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Radical scavenging effect of gliclazide in diabetic rats fed with
a high cholesterol diet.
Background. Gliclazide is a sulphonylurea antidiabetic drug
with anti-oxidant effect due to its azabicyclo-octyl ring. We hy-
pothesized that gliclazide may have a beneficial effect on dia-
betic nephropathy via radical scavenging.
Methods. Streptozotocin-induced diabetic rats fed a 4%
cholesterol diet [high cholesterol-diabetes mellitus (HC-DM)]
(N = 12) were treated with gliclazide (HC-DM + gliclazide)
(N = 12) or glibenclamide (HC-DM + glibenclamide) (N =
12) after 2 weeks of the diabetes induction, and normal rat fed
with 4% cholesterol served as control [high cholesterol-control
(HC-control)] (N = 12). Renal expression of endothelial nitric
oxide synthase (eNOS) and intracellular adhesion molecule-1
(ICAM-1), oxidative stress production via nicotinamide ade-
nine dinucleotide phosphate (NAD(P)H) oxidase and antioxi-
dant enzyme manganese superoxide dismutase (MnSOD) were
evaluated at 4 weeks and renal damage was examined at
8 weeks.
Results. HC-DM showed significant increase in renal
NAD(P)H oxidase and reduction in MnSOD with a significant
increase in urinary lipid peroxidation products and H2O2 ex-
cretion compared to HC-control. Gliclazide treatment, but not
glibenclamide, significantly reduced the oxidative products and
NAD(P)H oxidase. There was no difference in renal eNOS ex-
pression between HC-DM and HC-control rats, and only gli-
clazide treatment enhanced eNOS expression. Renal damage
evaluated by increased glomerular macrophage migration via
enhanced ICAM-1 expression, mesangial matrix expansion, and
albuminuria was significantly increased in HC-DM, and they
were ameliorated by gliclazide but not by glibenclamide.
Conclusion. Gliclazide reduced oxidative stress in dia-
betic rats fed a high cholesterol diet with reduction of re-
nal NAD(P)H oxidase expression, enhanced MnSOD and
eNOS expression, and had a beneficial effect on glomerular
macrophage infiltration and mesangial expansion.
Recently focus has been given on the role of oxidative
stress in the development of diabetic complications. The
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major source of oxidative stress in diabetes is reactive
oxygen species (ROS) derived from superoxide anion
that is produced by nicotinamide adenine dinucleotide
phosphate (NAD(P)H) oxidase as well as mitochondrial
respiratory chain reaction, xanthine oxidase, nitric oxide
synthase (NOS), among others [1]. ROS induced by high
glucose directly damage cell via oxidation of cell mem-
brane, cytosolic enzymes, and DNA, and also activate
signaling of cell proliferation, adhesion molecules, and
fibrosis [2, 3]. In the kidney we have previously demon-
strated that phagocytic NAD(P)H oxidase components
are expressed in the glomerular cells and distal convo-
luted tubules [4], and their expression and ROS forma-
tion were increased in the early-stage diabetic rats [5].
Thus, the suppression of NAD(P)H oxidase or scaveng-
ing its products may be effective in preventing diabetic
nephropathy.
Because angiotensin II stimulates NAD(P)H oxidase
expression and activation in vasculature and in the kid-
ney [6–9], both angiotensin-converting enzyme (ACE)
inhibitor and angiotensin receptor blocker (ARB) can
effectively suppress NAD(P)H oxidase and decrease
microalbuminuria in diabetic rats [5]. Suppression of
NAD(P)H oxidase can be a possible mechanism of
renoprotection of ACE inhibitor or ARB in diabetic
nephropathy that has been shown in randomized clini-
cal trials [10–13]. Other strategy to prevent diabetic com-
plications by ROS includes superoxide dismutase (SOD)
mimetics that has been shown effective in animal studies
[14, 15].
The second generation sulphonylurea gliclazide, is
widely used to treat type 2 diabetes and has been
described to have antioxidant properties due to its
azabicyclo-octyl ring in vitro and in vivo independent
of glycemic control [16–18]. To evaluate the renoprotec-
tive effect of gliclazide by ROS scavenging, we tested
gliclazide in an insulinopenic diabetic model to rule out
insulin action on blood glucose that can itself increase
ROS [19, 20], fed with a high cholesterol diet to in-
crease macrophage migration and glomerular damage
[21–23], and compared with another sulfonylurea antidi-
abetic drug, glibenclamide.
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METHODS
Protocol 1
Female Sprague-Dawley rats weighing 180 to 240 g
(Charles River Laboratories, Shizuoka, Japan) were
housed in a temperature-and humidity-controlled room
with a 12-hour light/dark cycle and were fed standard
laboratory animal chow and had free access to tap wa-
ter. Diabetes mellitus (DM) was induced by a single tail
vein injection of streptozotocin (STZ), 60 mg/kg body
weight; N = 10) (Sigma Chemical Co., St. Louis, MO,
USA) diluted in citrate buffer, pH 4.5. Control rats (N =
10) were injected with an equal volume of citrate buffer.
Another set of DM and control rats (12 animals in
each group) were fed 4% cholesterol diet with 1%
cholic acid [high cholesterol-diabetes mellitus (HC-DM)
and high cholesterol-control (HC-control)] to increase
macrophage infiltration in the glomeruli. After 3 days, the
induction of diabetes was confirmed by measurement of
blood glucose concentration.
Four weeks after STZ injection 24-hour urine and
blood samples were collected. The animals were anes-
thetized with pentobarbital (50 mg/kg body weight). Ab-
dominal aorta was cannulated, the kidneys were retro-
grade perfused with ice-cold phosphate buffered saline
(PBS) and the right kidney was taken and immediately
frozen for Western blotting and the left kidney was per-
fused with periodate-lysine-paraformaldehyde (PLP) so-
lution and embedded in wax for immunohistochemical
study.
Protocol 2
Two weeks after STZ injection, HC-DM rats were ran-
domly divided into three groups matched for body weight
and blood glucose: (1) diabetic untreated (HC-DM)
(N = 12); (2) gliclazide-treated (HC-DM + gliclazide)
(N = 12); and (3) glibenclamide-treated (HC-DM +
glibenclamide) (N = 12). Gliclazide (150 mg/kg/day) and
glibenclamide (8.6 mg/kg/day) were donated by Dainip-
pon Pharmaceutical Co. Ltd., Osaka, Japan and were
given in the diet. Female Sprague-Dawley rats fed 4%
cholesterol diet with 1% cholic acid served as control
(HC-control) (N = 12). After 2 weeks of treatment
and 4 weeks of diabetes induction, 24-hour urine and
blood were collected and rats were sacrificed as described
above.
Another set of five rats in each of the four groups under-
went the same procedures as described above and were
treated until 8 weeks after STZ injection. They were used
for evaluation of the effects of treatment on renal dam-
age, including glomerular macrophage migration, mesan-
gial matrix expansion, and albuminuria. All procedures
were conducted in conformance with the Guide for An-
imal Experimentation of the Faculty of Medicine of the
University of Tokyo.
Western blotting
As described in detail previously [5, 9] kidneys were ho-
mogenized on ice with a Teflon-glass tissue homogenizer
(Iwaki, Chiba, Japan) in 3 mL of 20 mmol/L Tris and ho-
mogenates were centrifuged at 4◦C and 12,000 rpm for
20 minutes. The supernatants were diluted in the same
volume of sodium dodecyl sulfate (SDS) buffer and sam-
ples containing 25 lg of protein were applied to 4% to
20% gradient gel (Daiichi Pure Chemicals Co., Tokyo,
Japan) and electroblotted to nitrocellulose membranes.
The membranes were incubated with 5% nonfat dried
milk in Tris-buffered saline containing 0.1% Tween 20
(TBST) for 30 minutes, following overnight incubation
with 15 lg/mL of monoclonal antibody for 4-hydroxy-2-
nonenal (4-HNE) (JaICA, Shizuoka, Japan), monoclonal
antibody for p47phox (Transduction Laboratories, Lex-
ington, KY, USA), monoclonal antibody for manganese
SOD (MnSOD) (Transduction Laboratories, Lexington,
KY, USA), polyclonal antibody for endothelial nitric ox-
ide synthase (eNOS) (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA), in a 1:1000 dilution and mon-
oclonal antibody for intracellular adhesion molecule-1
(ICAM-1) (Serotec, Oxford, England) in a 1:100 dilution.
After rinsing in TBST, membranes were incubated for
2 hours with a horseradish peroxidase (HRP)-conjugated
secondary antibody against mouse IgG (Dako, Glostrup,
Denmark) for 4-HNE, p47phox, MnSOD, and ICAM-1,
or against rabbit IgG (Dako) for eNOS in a 1:1000 dilu-
tion, and rinsed with TBST followed by 0.8 mmol/L di-
aminobenzidine (DAB) with 0.01% H2O2 and 3 mmol/L
NiCl2 for the detection of blots. The density of the
bands was analyzed using NIH image analyzer computer
program.
Immunohistochemistry and morphologic studies
The tissues were embedded in wax for periodic
acid-Schiff staining (PAS) and light microscopic immuno-
histochemistry. Kidney slices were processed for im-
munohistochemistry using the labeled streptavidin-biotin
method as described previously [5, 9]. Sections (2 lm)
were dewaxed, incubated with 3% H2O2, blocking serum,
and thereafter with a polyclonal antibody against eNOS
(Santa Cruz Biotechnology, Inc.) and monoclonal anti-
body against endothelin-1 (ED-1) (BMA Biomedicals
AG, Augst, Switzerland) at 1:100 dilution. The sections
were rinsed with TBST and biotinylated secondary anti-
body against rabbit IgG (Dako) for eNOS, or mouse IgG
(Dako) for ED-1 in a 1:400 dilution. After rinsing with
TBST, the sections were incubated with HRP-conjugated
streptavidin solution (Dako). HRP labeling was detected
using a peroxide substrate solution with 0.8 mmol/L
DAB and 0.01% H2O2. The sections were counterstained
with hematoxylin before being examined under a light
microscope.
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Mesangial matrix expansion was analyzed in all
glomeruli of each section as S0 for a normal glomeru-
lus; S1, <25% of glomerular area; S2, 25% to 50%; S3,
50% to 75%; S4, >75%. The degree of mesangial matrix
expansion was expressed as: mesangial matrix expansion
index = [0 × number of S0 + 1 × number of S1 + 2 ×
number of S2 + 3 × number of S3 + 4 × number of
S4]/[number of S0 + number of S1 + number of S2 +
number of S3 + number of S4]. The number of glomeru-
lar macrophage infiltration was calculated as a mean of
all glomeruli in each cross-section from each animal.
Measurement of glucose, H2O2, lipid peroxidation prod-
ucts, nitrite, creatinine, blood lipids, and albuminuria
All procedures for measurements were described
in detail in our previous reports [5, 24]. Blood
glucose was measured by Glutest E II (Kyoto Dai-
iti Kagaku, Kyoto, Japan). The H2O2 production
was measured by oxidation of nonfluorescent 2′,7′-
dichlorodihydrofluorescin-diacetate (DCFH-DA) to
the fluorescent 2′,7′-dichlorodihydrofluorescein (DCF).
Samples were incubated with 16 lL/mL final concentra-
tion of DCFH-DA for 20 minutes at 37◦C, and highly
fluorescent DCF formed in the presence of H2O2 was
measured in a spectrofluorometer (Hitachi F-2000)
(Hitachi, Tokyo, Japan) with wavelength at 485/535 nm.
The lipid peroxidation products (LPO) were measured
by thiobarbituric acid method. Briefly, after precipitation
of proteins, 100 lL of urine was incubated with 100 lL of
4% sodium dodecyl sulfate (SDS), 400 lL of 20% acetic
acid at pH 3.5 and 400 lL of 0.8% 2-thiobarbituric acid
(TBA) (Wako Pure Chemical Industries LTD., Osaka,
Japan) for 60 minutes at 95◦C. The malondialdehyde
(MDA) formation was measured with a spectrofluorom-
eter with an excitation/emission wavelength at 515/553
nm. Urinary excretion of nitrite was measured according
to the Griess method as described previously [24]. After
precipitation of protein by adding an equal amount
of 0.3 N NaOH and 5% ZnSO4 and centrifugation at
6400 rpm during 20 minutes, supernatants were reacted
with Griess solution, and nitrite was measured with a
spectrophotometer at 540 nm wavelength. Creatinine in
urine and blood was measured by Jaffe method using
spectrophotometer. Blood total cholesterol and triglyc-
erides were measured with an autoanalyzer. Urinary
albumin was quantified by enzyme-linked immunosor-
bent assay (ELISA) kit (Panaform Lab., Kumamoto,
Japan).
Statistics
All data were expressed as means ± SEM. The analysis
of variance with Bonferroni’s post hoc test was used for
statistical comparisons in the data with normal distribu-
tion, including mesangial matrix expansion index, mean
Table 1. Data of experimental animals fed a normal diet or high
cholesterol diet at 4 weeks of diabetes induction
Control DM HC-control HC-DM
(N = 10) (N = 10) (N = 12) (N = 12)
Densitometry 0.19 ± 0.01 0.26 ± 0.01a 0.21 ± 0.01 0.35 ± 0.02b,c,d
of p47phox
arbitrary
units
Urinary LPO 3.3 ± 0.4 7.1 ± 1.7a 17.7 ± 1.3b,e 125.2 ± 22.0b,d,e
excretion
nmol/mg
creatinine
Densitometry 0.25 ± 0.01 0.31 ± 0.01f 0.22 ± 0.01a,c 0.23 ± 0.01c
of eNOS
arbitrary
units
Densitometry 0.19 ± 0.01 0.26 ± 0.01a 0.24 ± 0.02f,g 0.32 ± 0.02b,e
of ICAM-1
arbitrary
units
Glomerular 0.05 ± 0.11 0.40 ± 0.03b 1.15 ± 0.07b,c 2.28 ± 0.10b,c,d
macrophage
infiltration
number
Abbreviations are: DM, diabetes mellitus rat; HC-control, control rat fed a
high cholesterol diet; HC-DM. diabetic rat fed a high cholesterol diet; eNOS,
endothelial nitric oxide synthase; ICAM-1, intracellular adhesion molecule-1;
LPO, lipid peroxidation product.
aP < 0.005; bP < 0.0001 vs. control; cP < 0.0001 vs. DM; dP < 0.0001 vs.
HC-control; eP < 0.005 vs. DM; fP < 0.05 vs. control; gP < 0.01 vs. DM.
glomerular macrophage infiltration number, densitome-
try of Western blot, and other biochemical measurements.
The data that did not show normal distribution such as
urinary albumin concentration were evaluated with non-
parametric analysis with Mann-Whitney test or logarith-
mically calculated before being submitted to analysis of
variance (ANOVA). P values less than 0.05 were required
for statistical significance.
RESULTS
Effect of high cholesterol diet in diabetes
We confirmed our previous publication [5] that diabetic
rats fed with a normal diet (DM) have an increased ex-
pression of NAD(P)H oxidase isoform, p47phox, with an
increased formation of superoxide anion and an increase
in eNOS expression in the kidney at 4 weeks (Table 1).
We evaluated the effect of a high cholesterol diet on
NAD(P)H oxidase isoform p47phox and eNOS in control
rats fed with a high cholesterol diet (HC-control) and di-
abetic rats fed with a high cholesterol diet (HC-DM) and
compared to animals fed with a normal diet.
We found that renal NAD(P)H oxidase p47phox was
significantly increased in high cholesterol diet compared
to normal diet in diabetic rats but not in control rats
(Table 1). Following p47phox increase, urinary LPO ex-
cretion was markedly increased in HC-DM compared to
DM. This effect was less prominent in HC-control com-
pared to control. Enhanced renal eNOS expression in
DM was decreased in HC-DM to the same level shown
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Table 2. Effect of gliclazide and glibenclamide treatment on physiologic data of high cholesterol–fed diabetic rats at 4 weeks
HC-control HC-DM HC-DM + gliclazide HC-DM + glibenclamide
(N = 12) (N = 12) (N = 12) (N = 12)
Body weight g 333 ± 29 254 ± 16a 264 ± 20a 258 ± 12a
Blood glucose mg/dL 129 ± 12 454 ± 23b 415 ± 27b 440 ± 20b
Hemoglobin A1c% 3.9 ± 0.7 11.9 ± 1.0b 11.6 ± 1.1b 11.3 ± 0.7b
(N = 8) (N = 6) (N = 6) (N = 6)
Mean blood pressure mm Hg 88 ± 7 83 ± 8 83 ± 7 86 ± 7
Creatine clearance mL/min/100 g body weight 1.19 ± 0.10 1.65 ± 0.17 1.98 ± 0.32a 1.71 ± 0.27
Total cholesterol mg/dL 230 ± 36 1499 ± 275b 1274 ± 139c 1234 ± 199c
Triglyceride mg/dL 26 ± 6 169 ± 20b 101 ± 15c,d 133 ± 26b
Kidney 4-HNE arbitrary units 0.24 ± 0.02 0.27 ± 0.01 0.22 ± 0.01d 0.26 ± 0.02
Urinary LPO excretion nmol/mg creatinine 17.7 ± 1.3 125.2 ± 22.0b 57.9 ± 13.0d 93.9 ± 25.4c
Nitrite in the kidney lmol/kidney 54.6 ± 3.0 57.7 ± 4.8 82.9 ± 14a.d.,e 56.4 ± 7.8
Urinary albumin excretion 5.7 ± 1.2 26.7 ± 6.0b 10.9 ± 2.0a,d,e 17.3 ± 4.1b
lg/mg creatinine/100 g body weight
Abbreviations are: HC-control, control rat fed a high cholesterol diet; HC-DM, diabetic rat fed a high cholesterol diet; 4-HNE, 4-hydroxy-2-nonenal; LPO, lipid
peroxidation product.
aP < 0.05; bP < 0.0001; cP < 0.05 vs. HC-control; dP < 0.05 vs. DM; eP < 0.05 vs. HC-DM + glibenclamide.
in HC-control (Table 1). There was a significant increase
in glomerular macrophage infiltration in DM compared
to control rats, and cholesterol diet addictively increased
macrophage migration in both groups however HC-DM
showed a more pronounced infiltration than HC-control
(Table 1). This increased macrophage migration can be
explained by the increased renal ICAM-1 expression
caused by the reduced eNOS and enhanced oxidative
stress in HC-DM rats (Table 1).
Effect of gliclazide and glibenclamide in physiologic
data and hemodynamics at 4 weeks of diabetes induction
Diabetic rats fed a high cholesterol diet (HC-DM)
at 4 weeks showed a significant increase in blood glu-
cose and hemoglobin A1c (HbA1c) and a reduction of
body weight, but no change in the mean blood pressure
compared to HC-control. The creatinine clearance was
slightly higher in HC-DM rats but the difference was
not significant under fasting condition (Table 2). Total
cholesterol and triglyceride were significant increased in
HC-DM than HC-control (Table 2). Treatment with gli-
clazide and glibenclamide did not change blood glucose
level, HbA1c, total cholesterol, and mean blood pres-
sure compared to HC-DM. Gliclazide-treated animals
(HC-DM + gliclazide) showed an increase in creatinine
clearance compared to control (HC-control) and a signif-
icant decrease in triglyceride levels compared to HC-DM
(Table 2).
Oxidative stress, NAD(P)H oxidase, and MnSOD
HC-DM rats showed a significant increase in LPO
excretion in urine and an increase tendency in kidney
4-HNE production compared to HC-control (Table 2).
Gliclazide treatment effectively decreased 4-HNE ex-
pression in the kidney and LPO production compared
to the HC-DM group, while no effect was observed with
glibenclamide (Table 2), indicating that only gliclazide
has a radical scavenging action.
NAD(P)H oxidase has been shown an important
source of oxidative stress and the quantitative analysis
of its component p47phox protein in the kidney showed
a specific band corresponding to a molecular weight of
47 kD by Western blotting. Densitometry of the band
showed increased protein amount in HC-DM compared
to HC-control rats (0.32 ± 0.02 vs. 0.23 ± 0.02 arbitrary
units, P < 0.01) (Fig. 1). This was decreased by treatment
with gliclazide (0.21 ± 0.02, P < 0.001 vs. HC-DM) but not
with glibenclamide (0.26 ± 0.02, NS vs. HC-DM) (Fig. 1).
On the other hand, Western blot analysis of the superox-
ide scavenge system, MnSOD protein in kidney showed
a band of 25 kD that was significantly decreased in the
HC-DM group compared to HC-control (0.20 ± 0.01 vs.
0.31 ± 0.02 arbitrary units, P < 0.0001) (Fig. 2), support-
ing the enhanced oxidative stress in HC-DM. Gliclazide
reversed this expression to the control level (0.30 ± 0.01,
NS vs. HC-control) (Fig. 2), but glibenclamide did not in-
crease MnSOD expression (0.19 ± 0.02, P < 0.0001 vs.
HC-control) (Fig. 2). The reduction of oxidative stress by
gliclazide may also be explained by the enhanced expres-
sion of MnSOD.
eNOS expression and nitrite production in the kidney
Nitric oxide produced by eNOS counteracts super-
oxide anion and has an inhibitory action on adhesion
molecules in the renal vessels, thus we examined eNOS
immunoreactivity in endothelial cells of renal arteries in
HC-DM rats. It was comparable to that in HC-control
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HC-DM
HC-DM + gliclazide
HC-DM + glibenclamide Fig. 1. Western blotting analysis of nicoti-
namide adenine dinucleotide phosphate
(NAD(P)H) oxidase isoform p47phox in the
kidney. Densitometry of bands at molecular
weight of 47 kD showed a significant increase
in NAD(P)H oxidase p47phox expression
in diabetic rats fed a high cholesterol diet
(HC-DM) compared to control rats fed
the same diet (HC-control). Treatment
with gliclazide (HC-DM + gliclazide) was
effective in lowering p47phox expression in
the kidney; however, this was not observed in
the glibenclamide-treated animals (HC-DM
+ glibenclamide). +P < 0.01 vs. HC-control;
∗P < 0.001 vs. HC-DM (N = 10 in each
group).
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Fig. 2. Western blotting analysis of man-
ganese superoxide dismutase (MnSOD). The
densitometry of MnSOD band at 25 kD
showed a significant decrease in diabetic rats
fed with a high cholesterol diet (HC-DM)
compared to control rats fed the same diet
(HC-control) at 4 weeks. Only treatment with
gliclazide (HC-DM + gliclazide), but not
glibenclamide (HC-DM + glibenclamide) re-
versed MnSOD to the control level. +P <
0.0001 vs. HC-control; ∗P < 0.0001 vs. HC-
DM; #P < 0.0001 vs. HC-DM + glibenclamide
(N = 10 in each group).
rat, and gliclazide treatment, but not glibenclamide, en-
hanced eNOS expression in renal vasculature (Fig. 3).
Western blot analysis confirmed no difference in eNOS
expression in HC-DM compared to HC-control rats
(0.24 ± 0.01 vs. 0.25 ± 0.01 arbitrary units, NS) (Fig. 4),
and increase in eNOS expression with gliclazide treat-
ment (0.29 ± 0.01, P < 0.05 vs. HC-DM) but no effect
with glibenclamide (0.22 ± 0.02, NS). These changes of
eNOS expression were confirmed by nitrite production
in the kidney. HC-DM did not show difference in nitrite
production compared to HC-control; however, gliclazide
treatment significantly increased nitrite production but
this was not observed with glibenclamide (Table 2).
ICAM-1 expression, macrophage infiltration,
and renal damage
The adhesion molecule ICAM-1 was up-regulated in
the kidney of diabetic rats compared to control (0.32 ±
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Fig. 3. Immunohistochemistry of endothelial nitric oxide synthase
(eNOS) in the renal artery. Immunoreactivity for eNOS in the endothe-
lial cells of renal artery showed no difference between control rats fed
a high cholesterol diet (HC-control) (A) and diabetic rats fed with a
high cholesterol diet (HC-DM) (B). Treatment of diabetic rats with gli-
clazide (HC-DM + gliclazide) (C) showed increased immunoreactivity
for eNOS but no effect with glibenclamide (HC-DM + glibenclamide)
(D) (magnification ×800).
0.02 vs. 0.19 ± 0.02 arbitrary units, P < 0.0001)
(Fig. 5). Following the increased protein expression of
ICAM-1 in the kidney, glomerular macrophage infiltra-
tion detected by immmunostaining with its maker ED-1
was significantly increased in diabetes (Fig. 6) and the
average number of macrophages in each glomerulus was
about two times higher in diabetic kidneys compared to
control (2.27 ± 0.10 vs. 1.15 ± 0.07, P < 0.0001). Gli-
clazide treatment significantly reduced ICAM-1 expres-
sion in the kidney (0.20 ± 0.01, P < 0.0001 vs. HC-DM)
(Fig. 5) followed by a decrease in macrophage infiltra-
tion in the glomeruli (1.85 ± 0.08, P < 0.0001 vs. HC-
DM) (Fig. 6) while glibenclamide treatment showed no
effect in ICAM-1 expression (0.29± 0.02, NS vs. HC-DM)
(Fig. 5) and macrophage infiltration (2.24 ± 0.08, NS vs.
HC-DM) (Fig. 6) compared to HC-DM rats. Diabetic
rats presented markedly increase in urinary albumin ex-
cretion, which was significantly reduced with treatment
with gliclazide (Table 2). Treatment with glibenclamide
showed no significant change in urinary albumin excre-
tion (Table 2).
Effect of gliclazide and glibenclamide on renal
damage at 8 weeks
At 8 weeks, HC-DM showed significant increase in
blood glucose and HbA1c compared to HC-control.
HbA1c value was not affected by gliclazide treatment;
however, glibenclamide-treated group showed a slight
decrease compared to nontreated diabetic rats. HC-DM
rats showed an increased oxidative stress evaluated by
urinary H2O2 excretion compared to HC-control, and
only gliclazide reduced it significantly (Table 3). Ni-
trite formation in the kidney did not show difference
at 8 weeks between HC-DM and HC-control, and treat-
ment with gliclazide significantly increased renal nitrite
(Table 3).
With the evolution of diabetic nephropathy, HC-DM
showed mesangial matrix expansion compared to HC-
control and further increase in glomerular macrophage
migration (Table 3). These renal changes were ac-
companied by increased urinary albumin excretion in
HC-DM compared to HC-control (Table 3). Gliclazide
treatment ameliorated mesangial matrix expansion and
decreased glomerular macrophage infiltration compared
to HC-DM, and showed a slight decrease in albumin-
uria that was statistically not different from HC-control
(Table 3). Glibenclamide showed no effect on these pa-
rameters of renal damage (Table 3).
DISCUSSION
In this study we firstly confirmed our previous report
[5] that showed enhanced NAD(P)H and eNOS in the
early stage of diabetes with normal diet, and we revealed
that high cholesterol diet increased oxidative stress
and glomerular macrophage migration in the kidney of
normal and diabetic rats by the enhanced NAD(P)H
oxidase p47phox expression and reduction of eNOS ex-
pression. Secondly we demonstrated a beneficial effect of
gliclazide in diabetic nephropathy independent of insulin
secretion and glycemic control. This effect of gliclazide is
due to scavenge of ROS via its azabicyclo-octyl ring struc-
ture, NAD(P)H oxidase suppression and up-regulation of
MnSOD, and also due to increased nitric oxide bioavail-
ability with enhanced eNOS leading to ICAM-1 suppres-
sion and reducing glomerular macrophage infiltration.
These beneficial effects were not observed with the other
sulphonylurea glibenclamide.
It has been shown that ROS production is enhanced
in diabetic rats via high glucose, de novo synthesis of
diacylglycerol, and enhanced protein kinase C (PKC),
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Fig. 4. Western blotting analysis for endothe-
lial nitric oxide synthase (eNOS) in kidney ho-
mogenates. The densitometry of eNOS band
at 133 kD showed no statistically significant
change between control (HC-control) and
diabetic rats (HC-DM) fed a high choles-
terol diet at 4 weeks. Treatment with gli-
clazide (HC-DM + gliclazide) up-regulated
eNOS expression. Glibenclamide (HC-DM
+ glibenclamide) did not have any effect on
eNOS expression in the kidney. +P < 0.05 vs.
HC-control; ∗P < 0.05 vs. HC-DM; #P < 0.005
vs. HC-DM + glibenclamide (N = 10 in each
group).
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Fig. 5. Western blotting analysis for intracel-
lular adhesion molecule-1 (ICAM-1) in kid-
ney. ICAM-1 showed a significant increase in
diabetic rats fed a high cholesterol diet (HC-
DM) compared to control animals given a
high cholesterol diet (HC-control) at 4 weeks,
and gliclazide (HC-DM + gliclazide) effec-
tively lowered ICAM-1 expression to control
levels. +P < 0.0005; ++P < 0.0001 vs. HC-
control; ∗P < 0.0001 vs. HC-DM; #P < 0.001
vs. HC-DM + glibenclamide (N = 10 in each
group).
p38 mitogen-activated protein kinase (MAPK) signals
and so on [2, 25]. We have previously demonstrated
that NAD(P)H oxidase expression and its products
are enhanced in the kidney of diabetic rat [5]. In this
study, we showed that the high cholesterol diet further
increased renal NAD(P)H oxidase in diabetic rats. In-
terestingly, MnSOD expression in the kidney was also
significantly decreased and this may have contributed to
a further enhancement of ROS in HC-DM rat compared
to HC-control rat. We showed that only gliclazide, but
not glibenclamide, could lower ROS production. The ef-
fect of gliclazide may depend on its specific molecular
structure with an azabicyclo-octyl ring to scavenge su-
peroxide anion and hydroxyl radicals [17, 26]. Moreover,
gliclazide also significantly inhibited NAD(P)H oxidase
and increased the expression of MnSOD in the kidney,
contributing to reduce ROS. Further studies are neces-
sary to reveal the mechanism of gliclazide stimulation of
MnSOD and inhibition of NAD(P)H oxidase.
The eNOS expression and its product nitric oxide have
an important role in the prevention of diabetic nephropa-
thy. The eNOS protein and mRNA levels were increased
in aorta of early phase diabetic rats to counterbalance the
increased degradation of nitric oxide by the reaction with
superoxide [27]. We have also previously demonstrated
that eNOS expression was increased in the kidney of early
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Fig. 6. Immunostaining for endothelin-1
(ED-1) in glomeruli. Macrophage infiltration
in glomeruli was observed by immunostaining
with the macrophage marker ED-1 at 4 weeks
in control rats fed a high cholesterol diet
(HC-control) (A), diabetic rats fed a high
cholesterol diet (HC-DM) (B), HC-DM
rats treated with gliclazide (HC-DM +
gliclazide) (C), and HC-DM rats treated with
glibenclamide (HC-DM + glibenclamide)
(D) (magnification ×360).
Table 3. Effect of gliclazide and glibenclamide treatment on high cholesterol–fed diabetic rats at 8 weeks
HC-control HC-DM HC-DM + gliclazide HC-DM + glibenclamide
(N = 5) (N = 5) (N = 5) (N = 5)
Blood glucose mg/dL 127.4 ± 8 532 ± 24a 578 ± 82b 439 ± 83a
Hemoglobin A1c% 2.7 ± 0.1 11.1 ± 0.7b 10.0 ± 0.8b 9.1 ± 0.7b,c
Urinary H2O2 excretion kFU/mg creatinine 6.9 ± 2.1 181.4 ± 18.5b 72.3 ± 11.2d,e,f 139.9 ± 28.3b
Nitrite in the kidney lmol/kidney 50.4 ± 3.0 28.2 ± 2.4b 40.9 ± 1.3d.e 34.3 ± 1.9a
Mesangial matrix 1.37 ± 0.03 2.56 ± 0.03b 2.07 ± 0.03b,g,h 2.56 ± 0.03b
expansion index
Mean glomerular macrophage 1.99 ± 0.11 4.33 ± 0.14b 2.44 ± 0.09d,g,h 4.15 ± 0.13b
infiltration number macrophage/glomerulus
Urinary albumin excretion 11.0 ± 2.1 40.4 ± 5.5d 31.8 ± 10.2 36.5 ± 10.5d
lg/mg creatinine/100 g body weight
Abbreviations are: HC-control, control rat fed a high cholesterol diet, HC-DM, diabetic rat fed high cholesterol diet.
aP < 0.005; bP < 0.0001 vs. control; cP < 0.05 vs. HC-DM; dP < 0.05 vs. HC-control; eP < 0.005 vs. HC-DM; fP < 0.05 vs. HC-DM + glibenclamide; gP < 0.0001 vs.
DM; hP < 0.0001 vs. HC-DM + glibenclamide.
phase of diabetes in rats accompanied by increased super-
oxide production and increased nitrosylation of proteins
by the reaction of nitric oxide with superoxide [5]. How-
ever, eNOS did not increase in HC-DM and this may be
explained by the evidence that a high cholesterol diet de-
creases eNOS protein amount in renal arteries [28]. Like-
wise, administration of antioxidants can prevent the fall
in eNOS expression in hypercholesterolemia [29]. We ob-
served that gliclazide, but not glibenclamide, effectively
increased eNOS expression and nitric oxide production
in the kidney. It was reported that eNOS deficiency and
plasma lipid dysfunction favors end-organ damage [30]
and compounds that specifically up-regulate this enzyme
are desirable for organ protection [31]. Thus, enhanced
eNOS and increased nitric oxide bioavailability by gli-
clazide may contribute to renoprotection in the diabetic
nephropathy.
The macrophages have been shown to play an impor-
tant role in the progression of glomerulosclerosis in dia-
betic nephropathy [21, 32, 33]. The increased infiltration
of macrophages follows the increased expression of ad-
hesion molecules. The adhesion molecule, ICAM-1, is up-
regulated in the early stage of diabetes and promotes the
recruitment of macrophages in diabetic glomeruli [34].
ICAM-1 is constitutively expressed in endothelial cells,
and its expression can be induced on mesangial cells and
epithelial cells by glucose, PKC, and intracellular free rad-
icals, angiotensin II, and cytokines via nuclear factor-jB
(NF-jB). On the other hand, nitric oxide down-regulates
its expression and impedes the adhesion of inflamma-
tory cells [34–36]. We have previously shown that eNOS
enhancement suppresses renal ICAM-1 expression and
decreases glomerular macrophage migration in the
nephrotoxic nephritis [24]. Similarly in this diabetic
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model, renal eNOS enhancement with increased ni-
tric oxide bioavailability by gliclazide suppressed the
ICAM-1 expression and decreased glomerular macro-
phage migration. This effect of gliclazide on macrophage
infiltration via adhesion molecules is consistent with pre-
vious reports in the retinal vasculature of diabetic rat and
human [37, 38]. Because the adhesion of phagocytes to
glomerular cells can further increase free oxygen rad-
ical production and cause renal damage, inhibition of
glomerular macrophage infiltration via suppression of
ICAM-1 may explain the reduction of albuminuria in the
HC-DM rat treated with gliclazide at 4 weeks.
With longer treatment with gliclazide at 8 weeks we
found a decreased production of H2O2 production and
decreased infiltration of macrophage and glomerular
matrix expansion in the HC-DM + gliclazide group.
Albuminuria was not significantly decreased in the
HC-DM + gliclazide group compared to the HC-DM
group, but it was not significantly increased compared
to HC-control. On the other hand, albuminuria was sig-
nificantly higher in the HC-DM + glibenclamide group
then in HC-control, suggesting that gliclazide is still ben-
eficial on albuminuria than glibenclamide in the longer
treatment. Jerums et al [39] did not find a significant re-
duction of albuminuria after 2 years of treatment with
gliclazide in humans; however, they could not totally ex-
clude the possibility of gliclazide in preventing the pro-
gression to overt diabetic nephropathy. It is possible that
the morphologic benefit seen with gliclazide in our study
results from its action on radical production. However, it
is also possible that this model is not totally transferable
to humans. At 8 weeks, HbA1c was slightly but not sig-
nificantly lower in HC-DM + gliclazide group and it was
significantly reduced in HC-DM + glibenclamide group
compared to HC-DM group; thus, the antidiabetic effect
of sulfonylureas on diabetic nephropathy cannot be com-
pletely excluded in the longer treatment.
CONCLUSION
Among the sulfonylurea antidiabetic drugs, gliclazide
has a specific characteristic of scavenging ROS, reduc-
ing the expression of NAD(P)H oxidase and enhancing
renal expression of MnSOD and eNOS. Increased nitric
oxide bioavailability by gliclazide suppressed glomerular
macrophage migration via decrease in ICAM-1 expres-
sion and ameliorated glomerular matrix expansion and
albuminuria.
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